International Experts Commend Riyadh’s Lifestyle Transformation Projects
5.5.2019 15:08:00 EEST | Business Wire | Press release
A panel of prominent International experts from various academic and professional fields convened yesterday to discuss Riyadh’s USD23 billion investment in the recently announced 4 Grand Projects that will transform the city and improve the wellbeing of millions of citizens in the capital city.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190505005026/en/
Group picture of the international experts attending Riyadh’s Lifestyle Transformation Forum (Photo: AETOSWire)
The Subject Matter Expert (SME) Forum took place at the Exhibition Centre King Fahad Library Plaza on 1st and 2nd May 2019. Discussion centered on a number of topics, including sustainable urban development, conservation, socio-economic well-being, art and culture, and the facilitation of a healthy lifestyle for all citizens.
The 4 Wellbeing Projects will greatly improve Saudis’ way of life by providing a greener, healthier environment and by encouraging participation in cultural and sporting life, in line with the Kingdom’s Vision 2030. These four projects are part of a massive development plan for the capital Riyadh, highlighting the Kingdom's leadership in sustainable urbanization and environmental management.
The Projects are: King Salman Park – one of the world’s largest urban parks with a land area of 13 km2, roughly four times that of Central Park in New York. The park, in addition to its large green spaces, will include a national theatre, opera house and art academy, and will host entertainment, environmental and cultural events. Green Riyadh – an urban greening project that will reduce CO2 levels and cool the city by up to 2°C. Green Riyadh will see 7.5 million trees planted in gardens, parks, mosques, schools and around the capital’s governmental and health sectors. Riyadh Art – a citywide gallery that will include 1,000 works of art and interactive installations, placed in residential areas, public parks, transport facilities and on Riyadh’s roads. Sports Boulevard – the first of its kind in the region, will feature 135 km of multi-purpose track for walking, running, cycling and horse riding.
“What I’ve seen over these two days is very much at the cutting edge and redefines what a city could be. What Riyadh is doing here I haven’t seen anywhere else in the world – where the planning is so integrated and well thought through, and innovative thinking is so evident. Riyadh is setting the standard. I commend these 4 Grand Projects,” John Rossant, Chairman & Founder, New Cities Foundation.
“Every one of these Wellbeing Projects is quite extraordinary. Riyadh will be transformed in ways that you and I can’t fully understand. They will transform this city not just in its infrastructure and facilities, but will transform health, culture and the very way citizens live their lives,” said Dr. David Griggs, Professor, Sustainable Development Institute, Monash University.
“The scale of these city projects is really impressive. Planting a few trees is nice. Maybe planting a couple of blocks is worthy. But it’s only when you get to the scale of 7.5 million trees and 9% green coverage of the city that you can actually change the climate and cool the city down,” John Englander, Oceanographer & Author, commenting on the 7.5 million trees that will be planted as part of the Riyadh Green Project.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190505005026/en/
Contact information
Riyadh Development Authority
Riyadh, Kingdom of Saudi Arabia
Arch.
Khalid Al-Hazani, Director, Architectural Projects Program & Public
Affairs
+966544777772, hazzani@ada.gov.sa
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
